ACTRN12621000042842
Recruiting
未知
A Phase II trial evaluating feasibility, safety and efficacy of an individually-tailored exercise intervention during chemotherapy for recurrent ovarian cancer(ECHO-R)
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Recurrent Ovarian Cancer
- Sponsor
- Griffith University
- Enrollment
- 80
- Status
- Recruiting
- Last Updated
- 3 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Women with recurrent ovarian, peritoneal or fallopian tube cancer of all types (including epithelial, germ cell, stromal, granulosa cell) and a platinum\-free interval of at least 6 months (platinum\-sensitive disease)
- •2\. Scheduled to receive, or currently receiving, chemotherapy (of any type).
- •3\. Age 18 years or over
- •4\. Willing and able to comply with all study requirements, including the exercise intervention, timing and nature of required assessments (note: face to face assessment is dependant on factors including timing and location, and does not constitute an exclusion criteria).
- •5\. Sufficiently fluent in English to fully participate in data collection requirements and comprehend intervention requirements
- •6\. Signed written informed consent
Exclusion Criteria
- •Serious medical or psychiatric conditions that might limit the ability of the patient to comply with the protocol.
- •NOTE: Since exercise safety has been demonstrated in a range of chronic disease settings such as cardiovascular disease, osteoarthritis and stroke, and the intervention is tailored to each woman’s capacity, the presence of other co\-morbidities will NOT preclude participation if all other eligibility criteria are met.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
A clinical trial aiming to assess the safety and activity of the combination of cabozantinib plus lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)gastroenteropancreatic (GEP) and thoracic neuroendocrine tumor (NET)MedDRA version: 20.0Level: SOCClassification code 10029104Term: Neoplasms benign, malignant and unspecified (incl cysts and polyps)System Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2019-004506-10-ITFONDAZIONE IRCCS ISTITUTO NAZIONALE DEI TUMORI69
Active, not recruiting
Phase 1
A clinical trial investigating how effective and safe the combination of drugs rituximab and pembrolizumab is at treating patients with Waldenström's Macroglobulinaemia that have not responded to their initial treatment or their disease has come back after being treated.Relapsed and refractory Waldenström's MacroglobulinaemiaMedDRA version: 21.0Level: PTClassification code 10047801Term: Waldenstrom's macroglobulinaemiaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-001767-23-GBniversity College London42
Active, not recruiting
Phase 1
Trastuzumab and AUY922 in HER2-aberrant NSCLCAdvanced non-smallcell lung cancer with HER2 - overexpression or - amplification or - mutationMedDRA version: 17.1Level: PTClassification code 10061873Term: Non-small cell lung cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2011-005655-13-DEniversity of Cologne29
Active, not recruiting
Phase 1
A phase II trial to evaluate safety and efficacy of adding durvalumab (MEDI4736) to standard neoadjuvant radiochemotherapy and of adjuvant durvalumab +/- tremelimumab in locally advanced esophageal adenocarcinoma and to evaluate biomarkers predictive for response to immune checkpoint inhibitiolocally advanced esophageal adenocarcinomaMedDRA version: 20.0Level: LLTClassification code 10001173Term: Adenocarcinoma of esophagusSystem Organ Class: 100000004864Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-003048-22-DEniversität zu Köln56
Not yet recruiting
Phase 2
A phase II trial to evaluate safety and efficacy of combined trastuzumab and AUY922 in advanced non-small cell lung cancer (NSCLC) with HER2 - overexpression or -amplification or - mutation.HER2-overexpression or -amplification or -mutationC34Malignant neoplasm of bronchus and lungDRKS00003301niversität Köln29